Gilead Sciences, Inc. (Nasdaq: GILD) today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. The offer remains at a purchase price of (1) $115.00 per share, net to the seller in cash, without interest, subject to any withholding tax, plus (2) one contractual contingent value right (CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, payable on March 31, 2030, subject to cumulative worldwide sales of Arcellx’s anitocabtagene autoleucel (anito-cel) product exceeding $6.0 billion on or prior to December 31, 2029..

吉利德科学公司（纳斯达克股票代码：GILD）今天延长了收购阿瑟勒克斯所有已发行普通股的要约期限。收购价格保持不变，为每股115.00美元现金（净价，不计利息，可能受预扣税影响），另加一个合同约定的或有价值权（CVR）。该CVR代表在2030年3月31日获得每股5.00美元的或有支付权利（现金支付，不计利息，可能受预扣税影响），但条件是阿瑟勒克斯的anitocabtagene autoleucel（anito-cel）产品在2029年12月31日或之前累计全球销售额超过60亿美元。

The tender offer, which was previously scheduled to expire at one minute after 11:59 p.m., Eastern Time, on April 2, 2026, has been extended to expire at 5:00 p.m., Eastern Time, on April 24, 2026. The transaction is anticipated to close during the second quarter of 2026, subject to the satisfaction or waiver of customary closing conditions, including the tender of a number of shares of Arcellx common stock that, together with shares already owned by Gilead, equals at least a majority of the then-outstanding Arcellx shares, the receipt of regulatory approvals and other customary offer conditions..

此前，要约收购预计于美国东部时间 2026 年 4 月 2 日晚上 11 点 59 分后一分钟到期，但现在已延长至美国东部时间 2026 年 4 月 24 日下午 5 点到期。本次交易预计将于 2026 年第二季度完成，但需满足或豁免惯例的交割条件，包括收到一定数量的 Arcellx 普通股股票（与吉利德已持有的股份合计占至少多数当时流通在外的 Arcellx 股份），获得监管机构批准及其他惯例要约条件。

Computershare Trust Company, N.A., the depositary and paying agent for the tender offer, has advised Gilead that, as of 5:00 p.m., Eastern Time, on March 31, 2026, approximately 4,389,763 shares have been validly tendered and not validly withdrawn in the tender offer, representing approximately 7.5% of the outstanding shares as of such date and time.

Computershare信托公司（北美），作为要约收购的存款代理和支付代理，已告知吉利德，截至2026年3月31日东部时间下午5:00，已有约4,389,763股有效投标且未有效撤回，约占该日期和时间流通股的7.5%。

Holders that have previously tendered their shares do not need to re-tender their shares or take any other action in response to the extension of the tender offer. Questions or requests for assistance may be directed to Innisfree M&A Incorporated, the information agent for the tender offer, by calling toll free (877) 800-5182..

此前已提交股票的股东无需因要约收购的延期而重新提交股票或采取任何其他行动。如有疑问或需要帮助，请拨打免费电话 (877) 800-5182 联系要约收购的信息代理机构 Innisfree M&A Incorporated。

About Gilead Sciences

关于吉利德科学公司

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer.

吉利德科学公司是一家生物制药公司，三十多年来一直致力于医学领域的突破，旨在为全人类创造一个更健康的世界。公司致力于推进创新药物的研发，以预防和治疗危及生命的疾病，包括艾滋病、病毒性肝炎、新冠肺炎和癌症。

In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif..

2025年，吉利德宣布计划投资320亿美元，进一步加强其在美国的布局，为下一阶段的发现、就业创造和公共卫生准备提供动力，同时继续在全球范围内进行投资，确保世界各地的患者都能从其科学创新中受益。吉利德在全球35多个国家开展业务，总部位于加利福尼亚州福斯特城。

Forward-Looking Statements

前瞻性声明

This communication contains forward-looking statements related to Gilead, Arcellx and the acquisition of Arcellx by Gilead that are subject to risks, uncertainties, and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of Gilead and Arcellx and members of their respective senior management teams.

本通讯包含关于吉利德、Arcellx 以及吉利德收购 Arcellx 的前瞻性陈述，这些陈述受风险、不确定性和其他因素影响。除历史事实陈述之外的所有陈述均可被视为前瞻性陈述，包括所有关于吉利德和 Arcellx 及其各自高级管理团队成员的意图、信念或当前期望的陈述。

In some cases, forward-looking statements can be identified by the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “seek,” “may,” “plan,” “project,” “should,” “target,” “will,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.

在某些情况下，前瞻性陈述可以通过使用诸如“预期”、“相信”、“估计”、“预计”、“意图”、“寻求”、“可能”、“计划”、“项目”、“应该”、“目标”、“将”或这些词语的否定形式或其他类似表达来识别，尽管并非所有前瞻性陈述都包含这些词语。

Forward-looking statements include, without limitation, statements regarding the transaction and related matters, prospective performance and opportunities, post-closing operations and the outlook for the companies’ businesses, including, without limitation, filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to satisfy the various closing conditions and complete the transaction; and any assumptions underlying any of the foregoing.

前瞻性声明包括但不限于有关交易及相关事项的声明、未来的表现与机遇、交割后的运营以及公司业务的前景，包括但不限于与交易相关的申报和审批；交易预计完成的时间；满足各种交割条件并完成交易的能力；以及上述任何内容所依据的假设。

Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties.

投资者应注意，任何此类前瞻性陈述都不是未来业绩的保证，且涉及风险和不确定性，投资者被提醒不要过分依赖这些前瞻性陈述。由于诸多风险和不确定性，实际结果可能与当前预期有重大差异。

Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the.

可能导致实际结果与前瞻性陈述所预期的结果不同的风险和不确定性包括：对以下方面的不确定性。

Additional Information and Where to Find It

更多信息及其查找位置

In connection with the proposed acquisition of Arcellx, Gilead caused Purchaser to commence a tender offer to purchase all of the outstanding shares of common stock of Arcellx. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities of Arcellx, nor is it a substitute for any tender offer materials that Gilead, Ravens Sub, Inc.

关于拟收购Arcellx一事，Gilead促使买方发起要约收购，以购买Arcellx所有已发行的普通股。本通讯仅用于提供信息，既不是购买Arcellx证券的要约，也不是出售证券的要约征集，且不能替代Gilead、Ravens Sub, Inc.发布的任何要约收购材料。

or Arcellx has filed or will file with the SEC. A solicitation and an offer to buy securities of Arcellx is being made only pursuant to an offer to purchase and related materials that Gilead has filed with the SEC. Gilead has filed a Tender Offer Statement on Schedule TO with the SEC, and Arcellx has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer.

或Arcellx已提交或将要向美国证券交易委员会（SEC）提交。仅根据Gilead向SEC提交的购买要约及相关材料，才会进行对Arcellx证券的征求和购买要约。Gilead已向SEC提交了TO表格的要约收购声明，而Arcellx已就该要约收购向SEC提交了14D-9表格的征求/建议声明。

ARCELLX’S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER.

阿瑟尔的股东和其他投资者被敦促阅读要约收购材料（包括购买要约、相关的转送信函和某些其他要约收购文件）以及在14D-9表上的征集/建议声明，因为它们包含了在就要约收购做出任何决定之前应仔细阅读的重要信息。

The Offer to Purchase, the related letter of transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement on Schedule 14D-9, have been sent to all stockholders of Arcellx at no expense to them. The Tender Offer Statement on Schedule TO, the Solicitation/Recommendation Statement on Schedule 14D-9 and other related documents are made available for free at the SEC’s web site at www.sec.gov.

购买要约、相关的转送函以及某些其他要约文件，以及在附表14D-9上的征求/建议声明，已免费发送给Arcellx的所有股东。在附表TO上的要约声明、在附表14D-9上的征求/建议声明以及其他相关文件可在美国证券交易委员会网站www.sec.gov上免费获取。

Additional copies may be obtained for free by contacting Gilead or Arcellx. Free copies of these materials and certain other offering documents.

通过联系吉利德或Arcellx，可以免费获取更多副本。这些材料和某些其他发行文件的免费副本。

In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Gilead and Arcellx file annual, quarterly and current reports, proxy statements and other information with the SEC. Gilead’s and Arcellx’s filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov..

除购买要约、相关的转递函和某些其他要约收购文件以及征集/建议声明外，吉利德和Arcellx还向美国证券交易委员会（SEC）提交年度、季度和当前报告、代理声明及其他信息。吉利德和Arcellx向SEC提交的文件也可通过商业文档检索服务免费获取，并可在SEC维护的网站www.sec.gov上查阅。

Gilead, Kite, and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

吉利德、Kite 以及吉利德标志是吉利德科学公司或其相关公司的商标。

Gilead

吉列德

Ashleigh Koss, Media

阿什利·科斯，媒体

public_affairs@gilead.com

公共事务@gilead.com

Jacquie Ross, Investors

杰基·罗斯，投资者

investor_relations@gilead.com

投资者关系@gilead.com

Source: gilead.com

来源：gilead.com